Rare Diseases: Drug Discovery and Informatics Resource

A rare disease refers to any disease with very low prevalence individually. Although the impacted population is small for a single disease, more than 6000 rare diseases affect millions of people across the world. Due to the small market size, high cost and possibly low return on investment, only in recent years, the research and development of rare disease drugs have gradually risen globally, in several domains including gene therapy, enzyme replacement therapy, and drug repositioning. Due to the complex etiology and heterogeneous symptoms, there is a large gap between basic research and patient unmet needs for rare disease drug discovery. As computational biology increasingly arises researchers’ awareness, the informatics database on rare disease have grown rapidly in the recent years, including drug targets, genetic variant and mutation, phenotype and ontology and patient registries. Along with the advances of informatics database and networks, new computational models will help accelerate the target identification and lead optimization process for rare disease pre-clinical drug development.

[1]  W. Hauswirth,et al.  Self-complementary AAV-mediated gene therapy restores cone function and prevents cone degeneration in two models of Rpe65 deficiency , 2010, Gene Therapy.

[2]  O. Goker-Alpan,et al.  Time of Initiating Enzyme Replacement Therapy Affects Immune Abnormalities and Disease Severity in Patients with Gaucher Disease , 2016, PloS one.

[3]  R. Tagliaferri,et al.  Discovery of drug mode of action and drug repositioning from transcriptional responses , 2010, Proceedings of the National Academy of Sciences.

[4]  G. Stamatoyannopoulos,et al.  Plerixafor+G-CSF-mobilized CD34+ cells represent an optimal graft source for thalassemia gene therapy. , 2015, Blood.

[5]  Á. Atallah,et al.  Enzyme replacement therapy for Fabry disease , 2007 .

[6]  Zheng Li,et al.  Drug-Disease Association and Drug-Repositioning Predictions in Complex Diseases Using Causal Inference-Probabilistic Matrix Factorization , 2014, J. Chem. Inf. Model..

[7]  Cheng Zhu,et al.  Drug repositioning for orphan diseases , 2011, Briefings Bioinform..

[8]  Giovanni Colonna,et al.  Modeling of the Bacterial Mechanism of Methicillin-Resistance by a Systems Biology Approach , 2009, PloS one.

[9]  Dongqing Wei,et al.  The α7 nAChR selective agonists as drug candidates for Alzheimer's disease. , 2015, Advances in experimental medicine and biology.

[10]  R. Bazan,et al.  Enzyme replacement therapy for Anderson-Fabry disease. , 2016, The Cochrane database of systematic reviews.

[11]  A. J. Roman,et al.  Improvement and decline in vision with gene therapy in childhood blindness. , 2015, The New England journal of medicine.

[12]  A. Barabasi,et al.  Drug—target network , 2007, Nature Biotechnology.

[13]  P. Bork,et al.  Drug Target Identification Using Side-Effect Similarity , 2008, Science.

[14]  Stephen T. C. Wong,et al.  Toward better drug repositioning: prioritizing and integrating existing methods into efficient pipelines. , 2014, Drug discovery today.

[15]  Brian K. Shoichet,et al.  The incorporation of protein flexibility and conformational energy penalties in docking screens to improve ligand discovery , 2014, Nature chemistry.

[16]  S. Lai,et al.  Targeted high-efficiency, homogeneous myocardial gene transfer. , 2007, Journal of molecular and cellular cardiology.

[17]  P. Fisher,et al.  β-Lactam antibiotics offer neuroprotection by increasing glutamate transporter expression , 2005, Nature.

[18]  Irena Melnikova,et al.  Rare diseases and orphan drugs , 2012, Nature Reviews Drug Discovery.

[19]  H Moghadam,et al.  Scoring multiple features to predict drug disease associations using information fusion and aggregation , 2016, SAR and QSAR in environmental research.

[20]  P. Song,et al.  Innovative measures to combat rare diseases in China: The national rare diseases registry system, larger-scale clinical cohort studies, and studies in combination with precision medicine research. , 2017, Intractable & rare diseases research.

[21]  P. Aloy,et al.  Unveiling the role of network and systems biology in drug discovery. , 2010, Trends in pharmacological sciences.

[22]  Steven J. M. Jones,et al.  FORGE Canada Consortium: outcomes of a 2-year national rare-disease gene-discovery project. , 2014, American journal of human genetics.

[23]  Yi Li,et al.  Multi-algorithm and multi-model based drug target prediction and web server , 2014, Acta Pharmacologica Sinica.

[24]  O. Gabrielli,et al.  Update on treatment of lysosomal storage diseases. , 2007, Acta myologica : myopathies and cardiomyopathies : official journal of the Mediterranean Society of Myology.

[25]  L. Cardon,et al.  Use of genome-wide association studies for drug repositioning , 2012, Nature Biotechnology.

[26]  C. Hollak,et al.  Biochemical response to substrate reduction therapy versus enzyme replacement therapy in Gaucher disease type 1 patients , 2016, Orphanet Journal of Rare Diseases.

[27]  Y.Z. Chen,et al.  Ligand–protein inverse docking and its potential use in the computer search of protein targets of a small molecule , 2001, Proteins.

[28]  Kui Xu,et al.  Database identifies FDA-approved drugs with potential to be repurposed for treatment of orphan diseases , 2011, Briefings Bioinform..

[29]  Jin Han Lo,et al.  Elosulfase alfa: First Global Approval , 2014, Drugs.

[30]  A. Amalfitano,et al.  Recent advances in gene therapy for lysosomal storage disorders , 2015, The application of clinical genetics.

[31]  Chuang Liu,et al.  Prediction of Drug-Target Interactions and Drug Repositioning via Network-Based Inference , 2012, PLoS Comput. Biol..

[32]  J. Chou,et al.  Normoglycemia alone is insufficient to prevent long-term complications of hepatocellular adenoma in glycogen storage disease type Ib mice. , 2009, Journal of hepatology.

[33]  Jinxiang Han,et al.  Defining rare diseases in China. , 2017, Intractable & rare diseases research.

[34]  Youngmi Yoon,et al.  A Network-Based Classification Model for Deriving Novel Drug-Disease Associations and Assessing Their Molecular Actions , 2014, PloS one.

[35]  D. di Bernardo,et al.  Identification of small molecules enhancing autophagic function from drug network analysis. , 2010, Autophagy.

[36]  G. Nagel,et al.  Implementation of a population-based epidemiological rare disease registry: study protocol of the amyotrophic lateral sclerosis (ALS) - registry Swabia , 2013, BMC Neurology.

[37]  K. Tsuda,et al.  Mining Significant Substructure Pairs for Interpreting Polypharmacology in Drug-Target Network , 2011, PloS one.

[38]  François Schiettecatte,et al.  OMIM.org: Online Mendelian Inheritance in Man (OMIM®), an online catalog of human genes and genetic disorders , 2014, Nucleic Acids Res..

[39]  A. Vergara,et al.  Rare Diseases: A Current View , 2017 .

[40]  Xin Yao,et al.  Modularity-based credible prediction of disease genes and detection of disease subtypes on the phenotype-gene heterogeneous network , 2011, BMC Systems Biology.

[41]  Jianfeng Pei,et al.  Systems biology brings new dimensions for structure-based drug design. , 2014, Journal of the American Chemical Society.

[42]  S. Ortolano,et al.  Treatment of lysosomal storage diseases: recent patents and future strategies. , 2014, Recent patents on endocrine, metabolic & immune drug discovery.

[43]  F. Mavilio,et al.  Developing gene and cell therapies for rare diseases: an opportunity for synergy between academia and industry , 2017, Gene Therapy.

[44]  Igor Goryanin,et al.  Kinetic modelling of NSAID action on COX-1: focus on in vitro/in vivo aspects and drug combinations. , 2009, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[45]  Xing-Ming Zhao,et al.  Drug-Domain Interaction Networks in Myocardial Infarction , 2013, IEEE Transactions on NanoBioscience.

[46]  G. Vriend,et al.  A text-mining analysis of the human phenome , 2006, European Journal of Human Genetics.

[47]  Jean Bennett,et al.  Gene Therapy for Leber's Congenital Amaurosis is Safe and Effective Through 1.5 Years After Vector Administration , 2009, Molecular therapy : the journal of the American Society of Gene Therapy.

[48]  Asher Mullard Gene therapies advance towards finish line , 2011, Nature Reviews Drug Discovery.

[49]  E. Bender Gene therapy: Industrial strength , 2016, Nature.

[50]  Novel Treatments for Rare Cancers: The U.S. Orphan Drug Act Is Delivering-A Cross-Sectional Analysis. , 2016, The oncologist.

[51]  Dongqing Wei,et al.  Exploring the Ligand-Protein Networks in Traditional Chinese Medicine: Current Databases, Methods and Applications , 2014, Advances in experimental medicine and biology.

[52]  Peng Gang Sun,et al.  The human Drug-Disease-Gene Network , 2015, Inf. Sci..

[53]  M. Andreani,et al.  Allogeneic cellular gene therapy in hemoglobinopathies—evaluation of hematopoietic SCT in sickle cell anemia , 2012, Bone Marrow Transplantation.

[54]  Michael J. Keiser,et al.  Predicting new molecular targets for known drugs , 2009, Nature.

[55]  Manuel Corpas,et al.  DECIPHER: web-based, community resource for clinical interpretation of rare variants in developmental disorders. , 2012, Human molecular genetics.

[56]  Gang Feng,et al.  Disease Ontology: a backbone for disease semantic integration , 2011, Nucleic Acids Res..

[57]  P. Robinson,et al.  The Human Phenotype Ontology: a tool for annotating and analyzing human hereditary disease. , 2008, American journal of human genetics.

[58]  Thomas C. Wiegers,et al.  A CTD–Pfizer collaboration: manual curation of 88 000 scientific articles text mined for drug–disease and drug–phenotype interactions , 2013, Database J. Biol. Databases Curation.

[59]  R. Dwek,et al.  Imino sugar inhibitors for treating the lysosomal glycosphingolipidoses. , 2005, Glycobiology.

[60]  Jean Bennett,et al.  Safety and durability of effect of contralateral-eye administration of AAV2 gene therapy in patients with childhood-onset blindness caused by RPE65 mutations: a follow-on phase 1 trial , 2016, The Lancet.

[61]  Francesco Iorio,et al.  Identification of small molecules enhancing autophagic function from drug network analysis , 2010 .

[62]  P. Elliott,et al.  The heart in Anderson-Fabry disease and other lysosomal storage disorders , 2007, Heart.

[63]  Michael J. Keiser,et al.  Prediction and evaluation of protein farnesyltransferase inhibition by commercial drugs. , 2010, Journal of medicinal chemistry.

[64]  R. Hopkin,et al.  The management and treatment of children with Fabry disease: A United States-based perspective. , 2016, Molecular genetics and metabolism.

[65]  R. Solé,et al.  The topology of drug-target interaction networks: implicit dependence on drug properties and target families. , 2009, Molecular bioSystems.

[66]  A. Olowoyeye,et al.  Gene therapy for sickle cell disease. , 2010, The Cochrane database of systematic reviews.

[67]  S. Nagueh Anderson-Fabry Disease and Other Lysosomal Storage Disorders , 2014, Circulation.

[68]  M. Whyte Hypophosphatasia: Enzyme Replacement Therapy Brings New Opportunities and New Challenges , 2017, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[69]  Luonan Chen,et al.  Network-based drug repositioning. , 2013, Molecular bioSystems.

[70]  M. Cubellis,et al.  Fabry_CEP: a tool to identify Fabry mutations responsive to pharmacological chaperones , 2013, Orphanet Journal of Rare Diseases.

[71]  Armando Blanco,et al.  DrugNet: Network-based drug-disease prioritization by integrating heterogeneous data , 2015, Artif. Intell. Medicine.

[72]  S. Maiella,et al.  Orphanet et son réseau : où trouver une information validée sur les maladies rares , 2013 .

[73]  Xiaomin Luo,et al.  TarFisDock: a web server for identifying drug targets with docking approach , 2006, Nucleic Acids Res..

[74]  Luigi Naldini,et al.  Gene therapy returns to centre stage , 2015, Nature.

[75]  Caterina Bissantz,et al.  Conformational Changes of G Protein‐Coupled Receptors During Their Activation by Agonist Binding , 2003, Journal of receptor and signal transduction research.

[76]  Xiaofeng Liu,et al.  ChemMapper: a versatile web server for exploring pharmacology and chemical structure association based on molecular 3D similarity method , 2013, Bioinform..

[77]  M. Murray,et al.  Lysosomal Acid Lipase Deficiency , 2020, Contemporary Cardiology.

[78]  Luonan Chen,et al.  Drug repositioning framework by incorporating functional information. , 2013, IET systems biology.

[79]  Y. Z. Chen,et al.  Prediction of potential toxicity and side effect protein targets of a small molecule by a ligand-protein inverse docking approach. , 2001, Journal of molecular graphics & modelling.

[80]  A. Cheng,et al.  Challenges in orphan drug development and regulatory policy in China , 2017, Orphanet Journal of Rare Diseases.

[81]  Michael J. Keiser,et al.  Large Scale Prediction and Testing of Drug Activity on Side-Effect Targets , 2012, Nature.

[82]  Xing-Ming Zhao,et al.  Predicting drug targets based on protein domains. , 2012, Molecular bioSystems.

[83]  R. Moxley,et al.  If you build a rare disease registry, will they enroll and will they use it? Methods and data from the National Registry of Myotonic Dystrophy (DM) and Facioscapulohumeral Muscular Dystrophy (FSHD). , 2012, Contemporary clinical trials.

[84]  Alessandro Aiuti,et al.  Gene therapy for immunodeficiency due to adenosine deaminase deficiency. , 2009, The New England journal of medicine.

[85]  Maria Vittoria Cubellis,et al.  Drug repositioning can accelerate discovery of pharmacological chaperones , 2015, Orphanet Journal of Rare Diseases.

[86]  Charles H Jones,et al.  Overcoming Gene-Delivery Hurdles: Physiological Considerations for Nonviral Vectors. , 2016, Trends in biotechnology.

[87]  Yi Pan,et al.  Drug repositioning based on comprehensive similarity measures and Bi-Random walk algorithm , 2016, Bioinform..

[88]  F. Dhombres,et al.  Representation of rare diseases in health information systems: The orphanet approach to serve a wide range of end users , 2012, Human mutation.

[89]  A. Simeonov,et al.  Drug discovery and development for rare genetic disorders , 2017, American journal of medical genetics. Part A.

[90]  Peng Jiang,et al.  Molecular networks for the study of TCM Pharmacology , 2010, Briefings Bioinform..

[91]  L. Meijer,et al.  Inverse in silico screening for identification of kinase inhibitor targets. , 2007, Chemistry & biology.

[92]  J. Lamerdin,et al.  Identifying off-target effects and hidden phenotypes of drugs in human cells , 2006, Nature chemical biology.

[93]  Michael Q. Zhang,et al.  Network-based global inference of human disease genes , 2008, Molecular systems biology.

[94]  C. Hollak,et al.  The attenuated/late onset lysosomal storage disorders: Therapeutic goals and indications for enzyme replacement treatment in Gaucher and Fabry disease. , 2015, Best practice & research. Clinical endocrinology & metabolism.

[95]  K. Bushby,et al.  The TREAT-NMD care and trial site registry: an online registry to facilitate clinical research for neuromuscular diseases , 2013, Orphanet Journal of Rare Diseases.

[96]  Michael Brudno,et al.  PhenomeCentral: A Portal for Phenotypic and Genotypic Matchmaking of Patients with Rare Genetic Diseases , 2015, Human mutation.

[97]  Michael J. Keiser,et al.  Relating protein pharmacology by ligand chemistry , 2007, Nature Biotechnology.

[98]  A. Markham Migalastat: First Global Approval , 2016, Drugs.

[99]  Holger Fröhlich,et al.  Modeling ERBB receptor-regulated G1/S transition to find novel targets for de novo trastuzumab resistance , 2009, BMC Systems Biology.

[100]  François Schiettecatte,et al.  OMIM.org: Online Mendelian Inheritance in Man (OMIM®), an online catalog of human genes and genetic disorders , 2014, Nucleic Acids Res..

[101]  Ralf Hofestädt,et al.  RAMEDIS: a comprehensive information system for variations and corresponding phenotypes of rare metabolic diseases , 2010, Human mutation.

[102]  A. Chiang,et al.  Systematic Evaluation of Drug–Disease Relationships to Identify Leads for Novel Drug Uses , 2009, Clinical pharmacology and therapeutics.

[103]  Naruemon Pratanwanich,et al.  Pathway-based Bayesian inference of drug-disease interactions. , 2014, Molecular bioSystems.

[104]  M. Michaelides,et al.  Development of an optimized AAV2/5 gene therapy vector for Leber congenital amaurosis owing to defects in RPE65 , 2016, Gene Therapy.

[105]  Ivan Molineris,et al.  Drug repositioning for orphan genetic diseases through Conserved Anticoexpressed Gene Clusters (CAGCs) , 2013, BMC Bioinformatics.

[106]  P. van Damme,et al.  Early stages of building a rare disease registry, methods and 2010 data from the Belgian Neuromuscular Disease Registry (BNMDR) , 2014, Acta Neurologica Belgica.

[107]  G. Whitesides,et al.  Combinatorial computational method gives new picomolar ligands for a known enzyme , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[108]  Kai Huang,et al.  PharmMapper server: a web server for potential drug target identification using pharmacophore mapping approach , 2010, Nucleic Acids Res..

[109]  D. Lockhart,et al.  Treatment of Fabry's Disease with the Pharmacologic Chaperone Migalastat. , 2016, The New England journal of medicine.

[110]  P. Hajduk,et al.  Rational approaches to targeted polypharmacology: creating and navigating protein-ligand interaction networks. , 2010, Current opinion in chemical biology.

[111]  Maria F. Sassano,et al.  A Pharmacological Organization of G Protein-coupled Receptors , 2012, Nature Methods.

[112]  Lin He,et al.  Exploring Off-Targets and Off-Systems for Adverse Drug Reactions via Chemical-Protein Interactome — Clozapine-Induced Agranulocytosis as a Case Study , 2011, PLoS Comput. Biol..

[113]  R. Iyengar,et al.  Systems approaches to polypharmacology and drug discovery. , 2010, Current opinion in drug discovery & development.

[114]  Yaffa R Rubinstein,et al.  NIH/NCATS/GRDR® Common Data Elements: A leading force for standardized data collection. , 2015, Contemporary clinical trials.

[115]  Khader Shameer,et al.  Computational and experimental advances in drug repositioning for accelerated therapeutic stratification. , 2015, Current topics in medicinal chemistry.

[116]  E. Dmitrovsky,et al.  Differentiation therapy of acute promyelocytic leukemia with tretinoin (all-trans-retinoic acid). , 1991, The New England journal of medicine.